Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.therap.2021.05.004 http://scihub22266oqcxt.onion/10.1016/j.therap.2021.05.004 34049688!8114590!34049688     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Therapie 2021 ; 76 (4): 277-283 Nephropedia Template TP {{tp|p=34049688|t=2021. Efficacy of COVID-19 vaccines: From clinical trials to real life |pdf=|usr=}}{{34049688}} gab.com Text Efficacy of COVID-19 vaccines: From clinical trials to real life JO: Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34049688 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated both their safety and efficacy. Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might strongly impact the mortality which could change the course of the pandemic. Twit Text FOAVip Efficacy of COVID-19 vaccines: From clinical trials to real life ????Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34049688 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34049688 #FOAvip English Wikipedia <ref>{{Cite pmid|34049688}}</ref> Efficacy of COVID-19 vaccines: From clinical trials to real life #MMPMID34049688 Deplanque D; Launay O Therapie 2021[Jul]; 76 (4): 277-283 PMID34049688show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated both their safety and efficacy. Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might strongly impact the mortality which could change the course of the pandemic. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*immunology/*prevention & control/virology[MESH] |Child[MESH] |Clinical Trials as Topic[MESH] |Europe/epidemiology[MESH] |Humans[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology[MESH]Efficacy of COVID-19 vaccines: From clinical trials to real life (epmc).pdf DeepDyve Pubget Overpricing